Cagrilintide: A Long Acting Amylin Analog for the : Cardiology in Review Eloralintide In early studies, a new drug under investigation called eloralintide helped some adults lose nearly 50 pounds in under a year and it's not a GLP 1: https: bit.ly 43nPJnS Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet